Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 41Carcinoma, Non-Small-Cell Lung 28Lung Neoplasms 8Triple Negative Breast Neoplasms 6Neoplasm Metastasis 6Neoplasms 5Uterine Cervical Neoplasms 4Recurrence 2Mesothelioma 2Lymphoma, Non-Hodgkin 2Carcinoma 2Adenocarcinoma of Lung 2Adenocarcinoma 2Thoracic Neoplasms 1Stomach Neoplasms 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Nonhematologic Malignancies 1Non-Squamous Non-Small Cell Lung Cancer 1Non - Small Cell Lung Cancer NSCLC 1Neuroendocrine Tumors 1NSCLC 1Metatropic dwarfism 1Metastatic HER2-positive Breast Cancer 1Lung Diseases 1Lethal Congenital Contracture Syndrome 2 1HR+HER2- Breast Cancer 1HER2-positive Advanced Breast Cancer 1Desmoplastic Small Round Cell Tumor 1

Interventions

Capecitabine 77pembrolizumab 70Oxaliplatin 68Cisplatin 56Fluorouracil 52Paclitaxel 41Trastuzumab 37Nivolumab 35Leucovorin 27Docetaxel 27Irinotecan 22Ramucirumab 20Gemcitabine 15Bevacizumab 15S 1 (combination) 14Carboplatin 13atezolizumab 12apatinib 12fludarabine 11Cyclophosphamide 11tislelizumab 10Drug Therapy 10Injections 8130-nm albumin-bound paclitaxel 8trastuzumab deruxtecan 7durvalumab 7Ipilimumab 7Folfox protocol 7Albumin-Bound Paclitaxel 7titanium silicide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Stomach Neoplasms × Vinorelbine × Clear all
NCT02892123 2024-11-27

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Jazz Pharmaceuticals

Phase 1 Completed
279 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡